Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients (1ASSJHCQ)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04546542|
Recruitment Status : Active, not recruiting
First Posted : September 14, 2020
Last Update Posted : November 8, 2022
Introduction. Primary Sjögren's syndrome (pSS) is an autoimmune disease characterized by chronic inflammatory infiltration of the salivary and lacrimal glands causing dry eye and mouth. Multiple systemic manifestations can also occur. Hydroxychloroquine (HCQ), an antimalarial immunomodulator, has been used for the treatment of arthralgias, myalgia and constitutional symptoms resulting from pSS. However, there are no studies that evaluated whether blood levels of HCQ could influence in the therapeutic response, as has been reported in systemic lupus erythematosus (SLE).
Objectives. Analyze in patients with pSS receiving HCQ as part of their treatment: blood levels of HCQ; adherence using a questionnaire versus blood levels and the possible correlation of blood levels with the disease activity score in a cross-sectional evaluation followed by a longitudinal six-month assessment.
Patients and methods. Observational cross-sectional evaluation followed by a six-month longitudinal assessment, including patients with pSS receiving HCQ for at least 3 months at study admission. Patients will be evaluated clinically and the HCQ blood level measured at the beginning of the study (T0), at 3 months (T3), and at 6 months (T6). As there are no previous studies on blood levels of HCQ in patients with pSS, the sample of 75 patients was calculated based on the percentage of these patients currently using HCQ in our service (nearly 50%) and in the number of patients in current follow-up (about 150). We will evaluate 75 adult patients with pSS according to the classification criteria of the American-European Consensus Group 2002 and/or the American College of rheumatology (ACR) and the European League Against Rheumatism (EULAR) 2016, of both sexes and followed up regularly at the Sjögren Syndrome outpatient Clinic of the Rheumatology Service of "Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP)". The following will be used in the clinical evaluation: the xerostomia Inventory; the xerophthalmia questionnaire - Ocular Surface Disease Index (OSDI); the EULAR Sjögren Syndrome Reported Index (ESSPRI); the EULAR Sjögren Syndrome Disease Activity Index (ESSDAI); the Sjögren's Syndrome Disease Damage Index (SSDDI); the non-stimulated and stimulated salivary flow and the 8-item Morisky Medication Adherence Scale. Blood levels of HCQ will be measured by high performance liquid chromatography and tandem mass spectrometry.
|Condition or disease||Intervention/treatment|
|Sjogren's Syndrome||Other: Parallel Assignment|
|Study Type :||Observational|
|Estimated Enrollment :||75 participants|
|Official Title:||Analysis of Hydroxychloroquine Blood Levels in Patients With Primary Sjögren Syndrome and Possible Correlation With the Disease Activity|
|Actual Study Start Date :||October 1, 2020|
|Estimated Primary Completion Date :||September 30, 2023|
|Estimated Study Completion Date :||December 1, 2023|
pSS patients under Hydroxychloroquine (HCQ) 2016-AAO dose
Patients under Hydroxychloroquine (HCQ) 2016-American Academy of ophtalmology (AAO) dose will have HCQ blood levels, disease activity and adherence evaltuated at study entry and before 3 and 6-months.
Other: Parallel Assignment
We will evaluate 75 patients with pSS (Consenso Americano-europeu de 2002 / EULAR/ACR Classification Criteria, 2016) of both sexes at baseline and 6-months
Other Name: pSS
- Change from baseline of HCQ blood levels at 3 and 6 months [ Time Frame: Baseline, 3 and 6 months ]Hydroxychloroquine blood levels will be measure using liquid chromatography tandem Mass Spectrometry (LC-MS/MS), as previously described (PEDROSA et al., 2020).
- HCQ adherence in pSS patients [ Time Frame: Baseline, 3 and 6 months ]Will be analysed the possible correlation between MTA (measure for treatment adhernce - a quesionnaire of adherence) score and HCQ blood levels em ng/mL (using liquid chromatography tandem Mass Spectrometry (LC-MS/MS), as previously described (PEDROSA et al., 2020). For SLE patients, adherence by HCQ blood levels is defined when HCQ blood levels are >500 ng/mL, this value in pSS patients will be estimated using this 2 assessements
- Disease activity in pSS patients [ Time Frame: Baseline, 3 and 6 months ]We will evaluate the disease activity in pSS patients and correlate if HCQ blood levels can predict risk of disease acrivity
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04546542
|Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo|
|São Paulo, Sao Paulo, Brazil, 05403-000|
|Hospital das Clinicas da Faculdade de Medicina da USP|
|São Paulo, Brazil, 05403-000|